The MAPK/Erk signaling pathway is frequently aberrantly activated in T-ALL, as a result of IL7Rα, JAK1, KRAS, NRAS, BRAF mutations [52,53]. This evidence concerns the gene JAK1 and acute lymphoblastic leukemia.